Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
hERG1およびhERG1/インテグリンβ1に結合する単一特異性および二重特異性抗体
Document Type and Number:
Japanese Patent JP7378088
Kind Code:
B2
Abstract:
The present invention describes a bispecfic antibody composed of the variable domains (VH and VL) of two antibodies, hERG1 mAb (which binds the extracellular domain S5-P of hERG1) and of β1 integrin mAb TS2/16 or BV7, which bind the extracellular domain of β1 integrin. The present invention relates also to a novel anti-hERG1 molecule bearing a Cys in position 95 of the VH domain. The invention describes also their application for diagnostic and therapeutic purposes in oncology and other fields of medical sciences.

Inventors:
Arcangeli Anna Rosa
duranti claudia
Carraresi Laura
Crescioli Silvia
Application Number:
JP2020524672A
Publication Date:
November 13, 2023
Filing Date:
June 29, 2018
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
Universitat degli Studi di Florence
D.V.A.L. Tuscany S.R.L.
International Classes:
C12N15/13; A61K39/395; A61P35/00; C07K16/28; C07K16/30; C07K16/46; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12N15/63; C12P21/08
Domestic Patent References:
JP2017501185A
Foreign References:
WO2016020483A1
Other References:
β1integrin/hERG1 complex as a novel molecular target for antineoplastic therapy,ABCD CONGRESS 2011 RAVENNA,2011年09月08日,p. 58, P1.51
The Journal of Biological Chemistry,1994年02月25日,Vol. 269, No. 8,pp. 6124-6132
The complex between the beta1 integrin and hERG1 potassium channels as a new molecular target in antineoplastic therapy,European Journal of Cancer Supplements,Vol. 8, No. 5,p. 59, 225
Attorney, Agent or Firm:
Masao Sekiguchi